{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-401010","form_type":"8-K","ticker":"COAG","cik":"0002114044","company_name":"Hemab Therapeutics Holdings, Inc.","filed_at":"2026-09-24T20:03:23+00:00","discovered_at":"2026-09-24T20:04:00.077276+00:00","generated_at":"2026-09-24T20:04:30.099807+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Hemab appoints Keli Walbert to board and audit committee effective Sept 24, 2026","bullets":["Keli Walbert elected Class I director, term expiring at 2027 annual meeting; also joins Audit Committee.","Granted option to purchase 36,000 shares at closing price on Sept 24, 2026; vests monthly over 3 years.","Annual cash compensation $40,000 (board) plus $10,000 (Audit Committee); equity grants per policy.","Vesting accelerates in full on change of control; standard indemnification agreement applies.","No family relationships or reportable transactions with company; no arrangement behind election."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-401010","json":"https://secwatch.observer/filing/0001193125-26-401010.json","markdown":"https://secwatch.observer/filing/0001193125-26-401010.md","text":"https://secwatch.observer/filing/0001193125-26-401010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/0001193125-26-401010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/d35700d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T20:04:30.099807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"317c4483e2","claim":"Keli Walbert was elected as Director at Hemab Therapeutics Holdings, Inc..","evidence_excerpt":"On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/0001193125-26-401010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}